On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
Today on the Biorasi Few & Far Between Podcast: Host Melissa Alesse welcomes Jason Tardio, President and COO of Immunic Therapeutics, to the podcast...
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...
Why are advocacy and accessibility so important to rare diseases such as Batten Disease? On this week’s Few & Far Between podcast episode, Biorasi’s...